MK5172 /MK8742 — Competitive Intelligence Brief

MK5172 /MK8742 (MK5172 /MK8742) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct-acting antiviral combination (NS3/4A protease inhibitor + NS5A inhibitor). Area: Infectious Disease (Hepatitis C).

phase 3 Direct-acting antiviral combination (NS3/4A protease inhibitor + NS5A inhibitor) HCV NS3/4A protease and NS5A protein Infectious Disease (Hepatitis C) Small molecule

Target snapshot

MK5172 /MK8742 (MK5172 /MK8742) — Istituto Clinico Humanitas. MK5172/MK8742 is a combination of a hepatitis C virus NS3/4A protease inhibitor and an NS5A inhibitor that blocks viral replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
MK5172 /MK8742 TARGET	MK5172 /MK8742	Istituto Clinico Humanitas	phase 3	Direct-acting antiviral combination (NS3/4A protease inhibitor + NS5A inhibitor)	HCV NS3/4A protease and NS5A protein
Grazoprevir/Elbasvir	Grazoprevir/Elbasvir	Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein
Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]	Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]	Massachusetts General Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein
glecaprevir/pibrentasvir tablets	glecaprevir/pibrentasvir tablets	Raymond T. Chung, MD	marketed	Direct-acting antiviral combination (NS3/4A protease inhibitor + NS5A inhibitor)	HCV NS3/4A protease and NS5A protein
Grazaoprevir/Elbasavir	Grazaoprevir/Elbasavir	The HIV Netherlands Australia Thailand Research Collaboration	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein
Glecaprevir and Pibrentasvir	Glecaprevir and Pibrentasvir	Massachusetts General Hospital	marketed	Direct-acting antiviral combination (NS3/4A protease inhibitor + NS5A inhibitor)	HCV NS3/4A protease and NS5A protein
Post-transplant Grazoprevir and Elbasvir	Post-transplant Grazoprevir and Elbasvir	University of Maryland, Baltimore	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Direct-acting antiviral combination (NS3/4A protease inhibitor + NS5A inhibitor) class)

1. AbbVie · 1 drug in this class
2. Istituto Clinico Humanitas · 1 drug in this class
3. Massachusetts General Hospital · 1 drug in this class
4. Raymond T. Chung, MD · 1 drug in this class